Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Treatment of Intestinal Fibrosis in Experimental Inflammatory Bowel Disease by the Pleiotropic Actions of a Local Rho Kinase Inhibitor.

Holvoet T, Devriese S, Castermans K, Boland S, Leysen D, Vandewynckel YP, Devisscher L, Van den Bossche L, Van Welden S, Dullaers M, Vandenbroucke RE, De Rycke R, Geboes K, Bourin A, Defert O, Hindryckx P, De Vos M, Laukens D.

Gastroenterology. 2017 Oct;153(4):1054-1067. doi: 10.1053/j.gastro.2017.06.013. Epub 2017 Jun 19.

PMID:
28642198
2.

AMA0428, A Potent Rock Inhibitor, Attenuates Early and Late Experimental Diabetic Retinopathy.

Hollanders K, Hove IV, Sergeys J, Bergen TV, Lefevere E, Kindt N, Castermans K, Vandewalle E, van Pelt J, Moons L, Stalmans I.

Curr Eye Res. 2017 Feb;42(2):260-272. doi: 10.1080/02713683.2016.1183030. Epub 2016 Jul 11.

PMID:
27399806
3.

Rho kinase inhibitor AMA0526 improves surgical outcome in a rabbit model of glaucoma filtration surgery.

Van de Velde S, Van Bergen T, Vandewalle E, Kindt N, Castermans K, Moons L, Stalmans I.

Prog Brain Res. 2015;220:283-97. doi: 10.1016/bs.pbr.2015.04.014. Epub 2015 Jun 30. Review.

PMID:
26497796
4.

Design, synthesis and biological characterization of selective LIMK inhibitors.

Boland S, Bourin A, Alen J, Geraets J, Schroeders P, Castermans K, Kindt N, Boumans N, Panitti L, Vanormelingen J, Fransen S, Van de Velde S, Defert O.

Bioorg Med Chem Lett. 2015 Sep 15;25(18):4005-10. doi: 10.1016/j.bmcl.2015.07.009. Epub 2015 Jul 10.

PMID:
26233434
5.

Inhibition of Rho-Associated Kinase Prevents Pathological Wound Healing and Neovascularization After Corneal Trauma.

Sijnave D, Van Bergen T, Castermans K, Kindt N, Vandewalle E, Stassen JM, Moons L, Stalmans I.

Cornea. 2015 Sep;34(9):1120-9. doi: 10.1097/ICO.0000000000000493.

PMID:
26075454
6.

Design, synthesis, and biological evaluation of novel, highly active soft ROCK inhibitors.

Boland S, Bourin A, Alen J, Geraets J, Schroeders P, Castermans K, Kindt N, Boumans N, Panitti L, Fransen S, Vanormelingen J, Stassen JM, Leysen D, Defert O.

J Med Chem. 2015 May 28;58(10):4309-24. doi: 10.1021/acs.jmedchem.5b00308. Epub 2015 May 6.

PMID:
25898023
7.

The effect of AMA0428, a novel and potent ROCK inhibitor, in a model of neovascular age-related macular degeneration.

Hollanders K, Van Bergen T, Kindt N, Castermans K, Leysen D, Vandewalle E, Moons L, Stalmans I.

Invest Ophthalmol Vis Sci. 2015 Jan 27;56(2):1335-48. doi: 10.1167/iovs.14-15681.

PMID:
25626969
8.

Novel Roflumilast analogs as soft PDE4 inhibitors.

Boland S, Alen J, Bourin A, Castermans K, Boumans N, Panitti L, Vanormelingen J, Leysen D, Defert O.

Bioorg Med Chem Lett. 2014 Sep 15;24(18):4594-4597. doi: 10.1016/j.bmcl.2014.07.016. Epub 2014 Jul 12.

PMID:
25149511
9.

AMA0076, a novel, locally acting Rho kinase inhibitor, potently lowers intraocular pressure in New Zealand white rabbits with minimal hyperemia.

Van de Velde S, Van Bergen T, Sijnave D, Hollanders K, Castermans K, Defert O, Leysen D, Vandewalle E, Moons L, Stalmans I.

Invest Ophthalmol Vis Sci. 2014 Feb 18;55(2):1006-16. doi: 10.1167/iovs.13-13157.

PMID:
24474276
10.

3-[2-(Aminomethyl)-5-[(pyridin-4-yl)carbamoyl]phenyl] benzoates as soft ROCK inhibitors.

Boland S, Defert O, Alen J, Bourin A, Castermans K, Kindt N, Boumans N, Panitti L, Van de Velde S, Stalmans I, Leysen D.

Bioorg Med Chem Lett. 2013 Dec 1;23(23):6442-6. doi: 10.1016/j.bmcl.2013.09.040. Epub 2013 Sep 21.

PMID:
24119557
11.

MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy.

Halkein J, Tabruyn SP, Ricke-Hoch M, Haghikia A, Nguyen NQ, Scherr M, Castermans K, Malvaux L, Lambert V, Thiry M, Sliwa K, Noel A, Martial JA, Hilfiker-Kleiner D, Struman I.

J Clin Invest. 2013 May;123(5):2143-54. doi: 10.1172/JCI64365. Epub 2013 Apr 24.

12.

The antiangiogenic 16K prolactin impairs functional tumor neovascularization by inhibiting vessel maturation.

Nguyen NQ, Castermans K, Berndt S, Herkenne S, Tabruyn SP, Blacher S, Lion M, Noel A, Martial JA, Struman I.

PLoS One. 2011;6(11):e27318. doi: 10.1371/journal.pone.0027318. Epub 2011 Nov 7.

13.

The angiostatic protein 16K human prolactin significantly prevents tumor-induced lymphangiogenesis by affecting lymphatic endothelial cells.

Kinet V, Castermans K, Herkenne S, Maillard C, Blacher S, Lion M, Noël A, Martial JA, Struman I.

Endocrinology. 2011 Nov;152(11):4062-71. doi: 10.1210/en.2011-1081. Epub 2011 Aug 23.

PMID:
21862622
14.

Enhancement of T-cell-mediated antitumor response: angiostatic adjuvant to immunotherapy against cancer.

Dings RP, Vang KB, Castermans K, Popescu F, Zhang Y, Oude Egbrink MG, Mescher MF, Farrar MA, Griffioen AW, Mayo KH.

Clin Cancer Res. 2011 May 15;17(10):3134-45. doi: 10.1158/1078-0432.CCR-10-2443. Epub 2011 Jan 20.

15.

Sprouty1, a new target of the angiostatic agent 16K prolactin, negatively regulates angiogenesis.

Sabatel C, Cornet AM, Tabruyn SP, Malvaux L, Castermans K, Martial JA, Struman I.

Mol Cancer. 2010 Sep 2;9:231. doi: 10.1186/1476-4598-9-231.

16.

Small-molecule inhibitors of vascular adhesion protein-1 reduce the accumulation of myeloid cells into tumors and attenuate tumor growth in mice.

Marttila-Ichihara F, Castermans K, Auvinen K, Oude Egbrink MG, Jalkanen S, Griffioen AW, Salmi M.

J Immunol. 2010 Mar 15;184(6):3164-73. doi: 10.4049/jimmunol.0901794. Epub 2010 Feb 12.

17.

Molecular imaging of tumor angiogenesis using alphavbeta3-integrin targeted multimodal quantum dots.

Mulder WJ, Castermans K, van Beijnum JR, Oude Egbrink MG, Chin PT, Fayad ZA, Löwik CW, Kaijzel EL, Que I, Storm G, Strijkers GJ, Griffioen AW, Nicolay K.

Angiogenesis. 2009;12(1):17-24. doi: 10.1007/s10456-008-9124-2. Epub 2008 Dec 9.

PMID:
19067197
18.

Paramagnetic lipid-coated silica nanoparticles with a fluorescent quantum dot core: a new contrast agent platform for multimodality imaging.

Koole R, van Schooneveld MM, Hilhorst J, Castermans K, Cormode DP, Strijkers GJ, de Mello Donegá C, Vanmaekelbergh D, Griffioen AW, Nicolay K, Fayad ZA, Meijerink A, Mulder WJ.

Bioconjug Chem. 2008 Dec;19(12):2471-9. doi: 10.1021/bc800368x.

19.

Isolation of endothelial cells from fresh tissues.

van Beijnum JR, Rousch M, Castermans K, van der Linden E, Griffioen AW.

Nat Protoc. 2008;3(6):1085-91.

PMID:
18546599
20.

Angiostatic activity of the antitumor cytokine interleukin-21.

Castermans K, Tabruyn SP, Zeng R, van Beijnum JR, Eppolito C, Leonard WJ, Shrikant PA, Griffioen AW.

Blood. 2008 Dec 15;112(13):4940-7. doi: 10.1182/blood-2007-09-113878. Epub 2008 May 30.

21.

A transgenic Tie2-GFP athymic mouse model; a tool for vascular biology in xenograft tumors.

Hillen F, Kaijzel EL, Castermans K, oude Egbrink MG, Löwik CW, Griffioen AW.

Biochem Biophys Res Commun. 2008 Apr 4;368(2):364-7. doi: 10.1016/j.bbrc.2008.01.080. Epub 2008 Jan 29.

PMID:
18237547
22.

Tumor blood vessels, a difficult hurdle for infiltrating leukocytes.

Castermans K, Griffioen AW.

Biochim Biophys Acta. 2007 Dec;1776(2):160-74. Epub 2007 Aug 15. Review.

PMID:
17888580
23.

The angiostatic 16K human prolactin overcomes endothelial cell anergy and promotes leukocyte infiltration via nuclear factor-kappaB activation.

Tabruyn SP, Sabatel C, Nguyen NQ, Verhaeghe C, Castermans K, Malvaux L, Griffioen AW, Martial JA, Struman I.

Mol Endocrinol. 2007 Jun;21(6):1422-9. Epub 2007 Apr 3.

PMID:
17405903
24.

Effects of radiotherapy and chemotherapy on angiogenesis and leukocyte infiltration in rectal cancer.

Baeten CI, Castermans K, Lammering G, Hillen F, Wouters BG, Hillen HF, Griffioen AW, Baeten CG.

Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):1219-27.

PMID:
17145537
25.

Epigenetic regulation of tumor endothelial cell anergy: silencing of intercellular adhesion molecule-1 by histone modifications.

Hellebrekers DM, Castermans K, Viré E, Dings RP, Hoebers NT, Mayo KH, Oude Egbrink MG, Molema G, Fuks F, van Engeland M, Griffioen AW.

Cancer Res. 2006 Nov 15;66(22):10770-7.

26.

Proliferating endothelial cells and leukocyte infiltration as prognostic markers in colorectal cancer.

Baeten CI, Castermans K, Hillen HF, Griffioen AW.

Clin Gastroenterol Hepatol. 2006 Nov;4(11):1351-7. Epub 2006 Oct 23.

PMID:
17059898
27.

Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors.

Dirkx AE, oude Egbrink MG, Castermans K, van der Schaft DW, Thijssen VL, Dings RP, Kwee L, Mayo KH, Wagstaff J, Bouma-ter Steege JC, Griffioen AW.

FASEB J. 2006 Apr;20(6):621-30.

PMID:
16581970
28.

Tumor cell plasticity in Ewing sarcoma, an alternative circulatory system stimulated by hypoxia.

van der Schaft DW, Hillen F, Pauwels P, Kirschmann DA, Castermans K, Egbrink MG, Tran MG, Sciot R, Hauben E, Hogendoorn PC, Delattre O, Maxwell PH, Hendrix MJ, Griffioen AW.

Cancer Res. 2005 Dec 15;65(24):11520-8.

Supplemental Content

Loading ...
Support Center